|
|
|||||||
|
Advertisement
|
Lamictal®
Serious side effects of LamictalIn some patients, rash progresses to a systemic illness with fever, arthralgia, myalgia, lymphadenopathy, eosinophilia, and malaise. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis occur rarely. Based upon clinical trials and post-marketing reports, the risk of severe dermatologic reaction is 0.3% in adults and approximately 1% in children 16 years and younger. The risk factors for severe dermatologic reactions with Lamictal include:
Any rash should be evaluated promptly. It is generally recommended that Lamictal be discontinued at the first sign of rash, unless the rash is clearly not drug-related. On July 10, 2008, an advisory panel was convened by the Food and Drug Administration (FDA) to review data that the FDA had previously collected from drug studies showing an association between many of the antiepileptic drugs (AEDs) and suicidal ideation and behavior, which together are called suicidality. According to the FDA’s Alert, among the patients with epilepsy in these drug studies, 1 out of 1000 people taking the placebo (inactive substance) showed suicidality compared to approximately 3.5 out of 1000 people who took an AED. The FDA advisory panel voted to accept the FDA's data at its meeting on July 10. The FDA has provided the following information for patients, family members, and caregivers at www.fda.gov/cder/drug/InfoSheets/HCP/antiepilepticsHCP.htm.
We again urge patients and families to contact their doctor before stopping an epilepsy medication because this may possibly lead to seizures and worsening of mood. Reviewed July 2008 by Steven C. Schachter, MD, epilepsy.com Editorial Board. When a patient presents with a serious and/or unexpected adverse reaction from a medication or device, you should consider reporting this event to Medwatch (http://www.fda.gov/medwatch/report/hcp.htm). To download Medwatch reporting forms click here (http://www.fda.gov/medwatch/getforms.htm). |
||||||
|
© 2008 Epilepsy.com/professionals. All rights reserved.
Site Map |
Privacy Statement |
Terms of Use |
Problems? Email webmaster@epilepsytdp.org
|